GYRE logo

GYRE
Gyre Therapeutics Inc

9,446
Mkt Cap
$756.55M
Volume
77,264.00
52W High
$11.78
52W Low
$6.57
PE Ratio
345.13
GYRE Fundamentals
Price
$7.80
Prev Close
$7.68
Open
$7.68
50D MA
$7.63
Beta
1.48
Avg. Volume
54,776.87
EPS (Annual)
$0.0225
P/B
6.72
Rev/Employee
$186,540.80
$713.22
Loading...
Loading...
News
all
press releases
Gyre Therapeutics (NASDAQ:GYRE) Trading Up 2% - Should You Buy?
Gyre Therapeutics (NASDAQ:GYRE) Trading 2% Higher - Here's What Happened...
MarketBeat·18d ago
News Placeholder
More News
News Placeholder
Gyre Therapeutics (GYRE) to Release Earnings on Tuesday
Gyre Therapeutics (NASDAQ:GYRE) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 31. (View Earnings Report at...
MarketBeat·1mo ago
News Placeholder
Zacks Research Downgrades Gyre Therapeutics (NASDAQ:GYRE) to Strong Sell
Zacks Research lowered shares of Gyre Therapeutics from a "hold" rating to a "strong sell" rating in a report on Monday...
MarketBeat·1mo ago
News Placeholder
Gyre Therapeutics (NASDAQ:GYRE) Trading Down 8.2% - Time to Sell?
Gyre Therapeutics (NASDAQ:GYRE) Trading Down 8.2% - Should You Sell...
MarketBeat·1mo ago
News Placeholder
Gyre Therapeutics (NASDAQ:GYRE) Announces Earnings Results
Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) posted its earnings results on Thursday. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.04). The...
MarketBeat·2mo ago
News Placeholder
Gyre Therapeutics (NASDAQ:GYRE) Downgraded by Wall Street Zen to Hold
Wall Street Zen cut Gyre Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday...
MarketBeat·2mo ago
News Placeholder
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down - Should You Sell?
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down - What's Next...
MarketBeat·2mo ago
News Placeholder
Gyre Therapeutics, Inc. (GYRE) Q4 Earnings Miss Estimates
Gyre Therapeutics, Inc. (GYRE) delivered earnings and revenue surprises of -50.00% and +2.17%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of +87.50% and +20.41%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of +15.08% and +57.97%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
<
1
2
...
>

Latest GYRE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.